MX2021008696A - Metodos para tratar artritis reumatoide, urticaria espontanea cronica y lupus eritematoso diseminado mediante el uso de un inhibidor de tirosina quinasa de bruton. - Google Patents

Metodos para tratar artritis reumatoide, urticaria espontanea cronica y lupus eritematoso diseminado mediante el uso de un inhibidor de tirosina quinasa de bruton.

Info

Publication number
MX2021008696A
MX2021008696A MX2021008696A MX2021008696A MX2021008696A MX 2021008696 A MX2021008696 A MX 2021008696A MX 2021008696 A MX2021008696 A MX 2021008696A MX 2021008696 A MX2021008696 A MX 2021008696A MX 2021008696 A MX2021008696 A MX 2021008696A
Authority
MX
Mexico
Prior art keywords
methods
rheumatoid arthritis
tyrosine kinase
lupus erythematosus
treating rheumatoid
Prior art date
Application number
MX2021008696A
Other languages
English (en)
Spanish (es)
Inventor
Alyssa Morimoto
Tamiko Katsumoto
Leslie Chinn
David James Haddon
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2021008696A publication Critical patent/MX2021008696A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MX2021008696A 2019-01-22 2020-01-21 Metodos para tratar artritis reumatoide, urticaria espontanea cronica y lupus eritematoso diseminado mediante el uso de un inhibidor de tirosina quinasa de bruton. MX2021008696A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795477P 2019-01-22 2019-01-22
US201962913270P 2019-10-10 2019-10-10
PCT/US2020/014346 WO2020154252A1 (en) 2019-01-22 2020-01-21 Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
MX2021008696A true MX2021008696A (es) 2021-08-19

Family

ID=69726724

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021008696A MX2021008696A (es) 2019-01-22 2020-01-21 Metodos para tratar artritis reumatoide, urticaria espontanea cronica y lupus eritematoso diseminado mediante el uso de un inhibidor de tirosina quinasa de bruton.
MX2025013950A MX2025013950A (es) 2019-01-22 2021-07-19 Metodos para tratar artritis reumatoide, urticaria espontanea cronica y lupus eritematoso diseminado mediante el uso de un inhibidor de tirosina quinasa de bruton

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025013950A MX2025013950A (es) 2019-01-22 2021-07-19 Metodos para tratar artritis reumatoide, urticaria espontanea cronica y lupus eritematoso diseminado mediante el uso de un inhibidor de tirosina quinasa de bruton

Country Status (11)

Country Link
US (1) US12544372B2 (cg-RX-API-DMAC7.html)
EP (1) EP3914250A1 (cg-RX-API-DMAC7.html)
JP (3) JP2022523018A (cg-RX-API-DMAC7.html)
KR (1) KR20210119457A (cg-RX-API-DMAC7.html)
CN (3) CN113423401A (cg-RX-API-DMAC7.html)
AU (2) AU2020213265B2 (cg-RX-API-DMAC7.html)
CA (1) CA3125236A1 (cg-RX-API-DMAC7.html)
IL (1) IL284779A (cg-RX-API-DMAC7.html)
MX (2) MX2021008696A (cg-RX-API-DMAC7.html)
TW (1) TW202042815A (cg-RX-API-DMAC7.html)
WO (1) WO2020154252A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI907406B (zh) 2020-04-03 2025-12-11 美商建南德克公司 使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法
WO2024235166A1 (zh) * 2023-05-12 2024-11-21 武汉人福创新药物研发中心有限公司 含有btk抑制剂的组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011325134B2 (en) * 2010-11-05 2014-10-23 Novartis Ag Methods of treating rheumatoid arthritis using IL-17 antagonists
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
PL4049660T3 (pl) 2016-02-29 2025-06-09 F. Hoffmann-La Roche Ag Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona
WO2018175863A1 (en) 2017-03-24 2018-09-27 Genentech, Inc. Methods of treating autoimmune and inflammatory diseases

Also Published As

Publication number Publication date
CN113423401A (zh) 2021-09-21
AU2025201888A1 (en) 2025-04-03
EP3914250A1 (en) 2021-12-01
JP2026041743A (ja) 2026-03-10
AU2020213265B2 (en) 2025-01-16
CN118453606A (zh) 2024-08-09
JP2024099575A (ja) 2024-07-25
KR20210119457A (ko) 2021-10-05
CA3125236A1 (en) 2020-07-30
CN118662512A (zh) 2024-09-20
MX2025013950A (es) 2026-03-02
WO2020154252A1 (en) 2020-07-30
AU2020213265A1 (en) 2021-07-22
TW202042815A (zh) 2020-12-01
JP2022523018A (ja) 2022-04-21
IL284779A (en) 2021-08-31
US20220047588A1 (en) 2022-02-17
US12544372B2 (en) 2026-02-10

Similar Documents

Publication Publication Date Title
IL282468A (en) 2- amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
MX2025003987A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos
AR122787A2 (es) Inhibidores de kras g12c y métodos para su uso
CL2019002734A1 (es) Isoquinolinas como inhibidores de hpk1.
MX2021013662A (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
EP3371762A4 (en) SYSTEMS AND METHODS FOR POWER-CONTROLLED DYNAMIC GEOFENCE-BASED TARGETING
CR20160379A (es) Anticuerpos biespecificos anti-il 13/il-17 y sus usos
MX2019000216A (es) Compuestos, composiciones y metodos para el tratamiento de enfermedades.
MX2021015628A (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso.
CL2016000466A1 (es) Compuestos derivados de 2-amino pirimidina sustituida, inhibidores de bmi-1 composicion farmaceutica y uso en el tratamiento del cancer.
EA201891620A1 (ru) Ингибиторы взаимодействующей с рецептором протеинкиназы 1
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
BR112017002594A2 (pt) compostos inibidores de cinase de ligação de tank
MX389307B (es) Derivados de oxoisoquinolina novedosos
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
MX2018016257A (es) Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
MX2020012980A (es) Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina.
IL286983A (en) Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX395110B (es) Lamina de acero.
CR20180465A (es) Composiciones y métodos para tratar artritis reumatoide
AR110404A1 (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l